|
Prior to co-founding Tercica and assuming the role of chief executive officer, John A. Scarlett, MD founded and served as chief executive officer of another Genentech licensee, Sensus Drug Development Corporation through its drug approval for SOMAVERT and later sale to Pharmacia. Dr. Scarlett also co-founded biologics manufacturer Covance Biotechnology Services, Inc. (CBSI). Previously, Dr. Scarlett served as head of the North American Clinical Development Organization and senior vice president of Medical and Scientific affairs at Novo Nordisk Pharmaceuticals, Inc. Prior to Novo, Dr. Scarlett headed the clinical development group at Greenwich Pharmaceuticals, and served McNeil Pharmaceuticals (Johnson & Johnson) in several positions, including director of Medical Research and Services. Dr. Scarlett holds an MD with Honors from the University of Chicago's Pritzker School of Medicine and trained in Internal Medicine at the Hospital at the University of Pennsylvania, and in Endocrinology and Metabolism at the University of Colorado, where he was the recipient of the Solomon A. Berson Award of the American Diabetes Association (ADA). | 